(UTHR) United Therapeutics - Ratings and Ratios

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company dedicated to addressing severe and unmet medical needs, primarily in the field of pulmonary arterial hypertension (PAH) and other rare diseases. The company has developed a portfolio of therapies, including Tyvaso DPI, an inhaled dry powder formulation of iloprost delivered via pre-filled, single-use cartridges; Tyvaso, an inhaled solution administered via an ultrasonic nebulizer; Remodulin (treprostinil), a subcutaneous or intravenous injection for PAH patients; Orenitram, an oral treprostinil tablet designed to delay disease progression; and Adcirca, an oral PDE-5 inhibitor that improves exercise capacity in PAH patients. The company also markets Unituxin (dinutuximab), a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump, a delivery system for Remodulin. Its pipeline includes RemoPro and Ralinepag for PAH, Aurora-GT, a gene therapy aimed at rebuilding pulmonary blood vessels, and Nebulized Tyvaso for idiopathic pulmonary fibrosis. The company collaborates with DEKA Research & Development Corp. on a semi-disposable delivery system for treprostinil, MannKind Corporation on an inhalation powder formulation, and Arena Pharmaceuticals on Ralinepag. Founded in 1996, United Therapeutics is based in Silver Spring, Maryland.

Over the next three months, United Therapeutics stock is expected to face headwinds as technical indicators signal bearish momentum. The stock is trading below its SMA 20, SMA 50, and SMA 200, indicating downward pressure. With an ATR of 11.92, volatility is moderate, suggesting potential price swings within a defined range. Fundamental analysis shows a P/E ratio of 11.83, slightly above its forward P/E of 10.58, while a P/S ratio of 4.55 reflects premium pricing relative to sales. The RoE of 18.55% highlights efficient equity utilization. Based on these factors, the stock may experience sideways movement with potential resistance at the SMA 20 (295.51) and SMA 50 (317.57) levels. Support is likely to hold around the SMA 200 (345.59), though downside risks remain if the stock fails to reclaim its short-term moving averages. Investors should monitor pipeline developments and partnership progress for potential catalysts.